170684-14-7

UK 1745 is a novel cardiotonic drug.

UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure[1][2].

[1] Sawada, et al. "Pharmacological Characterization of Effects of UK-1745, a Novel Cardiotonic Agent withβ-Adrenoceptor-blocking Action, in Aequorin-loaded Canine Right Ventricular Muscle." Journal of molecular and cellular cardiology 31.5 (1999): 1047-1062. DOI:10.1006/jmcc.1999.0938
[2] Uchida, et al. "Cardiovascular effects of (2RS, 3SR)-2-aminomethyl-2, 3, 7, 8-tetrahydro-2, 3, 5, 8, 8-pentamethyl-6H-furo-[2, 3-e] indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties." Arzneimittel-forschung 48.3 (1998): 219-231. PMID:9553677